Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD).

This clinical trial is for men and women with newly diagnosed multiple myeloma who are not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT).
   
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
   

The purpose of this study is to test the safety of a drug called CA-4948 in combination with pembrolizumab for patients with metastatic urothelial cancer. This study tests different doses of the drug to determine the highest dose with manageable side effects in people.

This clinical trial is for adults who have been diagnosed with non-small cell lung cancer (NSCLC).

This clinical trial is for adults who have relapsed or refractory multiple myeloma (either their disease has come back, or it is no longer responding to their current treatment) and standard therapies available to treat their disease may have limited effectiveness.
   

The purpose of this study is to evaluate the safety and effectiveness of the Elevate System for patients needing non-emergent percutaneous coronary intervention (PCI).

The Elevate System is an investigational heart pump device, which means it has not been approved by the U.S. Food and Drug Administration (FDA). It is being compared with an already approved heart pump device called the Impella System. The Impella System is approved for patients having HR-PCI.

The purpose of this study is to evaluate the safety and efficacy of percutaneous endovascular catheter-facilitated intramyocardial delivery of XC001 in treating refractory angina compared to standard treatment.

The purpose of this study is to see if an experimental device, called the Shockwave Medical Inc. Reducer System (Reducer) is safe and useful in treating refractory angina compared to standard treatment.

Experimental means that the device is not approved by the U.S. Food and Drug Administration (FDA).

 The primary objective of the study is to evaluate the effectiveness and safety of brelovitug (BJT-778) as a long-term treatment in participants with chronic hepatitis delta virus (HDV) infection, the virus responsible for chronic hepatitis D (CHD).

BJT-778 is an investigational study drug, which  means that it is not an approved treatment for HDV infection by the U.S. Food and Drug Administration (FDA)    

We’d like to hear about the experience when getting cancer care among adults with colorectal, pancreatic, esophageal, or gastric cancer, who live in underserved communities in New York City.

This study is to better understand which challenges people face when obtaining care. Our goal is to identify opportunities to improve the process of obtaining care after being diagnosed with cancer.